| Inaugurating the Single-Topic Conference |
|
v | |
| Preface |
|
vii | |
| Organization of the Symposium |
|
xi | |
|
1 Therapy for Viral Hepatitis and Prevention of Hepatocellular Carcinoma |
|
|
|
1.1 Opening Lecture: What is Accomplished and What is Needed |
|
|
|
|
|
3 | (22) |
|
2 Lamivudine Therapy for Hepatitis B |
|
|
|
2.1 New Anti-Virals Against Wild-Type and Lamivudine-Resistant Hepatitis B Virus |
|
|
|
N. KATO, S.K. ONO-NITA, and M. OMATA |
|
|
25 | (7) |
|
2.2 Lamivudine Therapy of Hepatitis B in Japan |
|
|
|
|
|
32 | (6) |
|
2.3 Early Detection of Lamivudine Resistant Mutant in Chronic Hepatitis B Patients Using a Novel Sensitive Method |
|
|
|
T. OKANOUE, K. MORI, T. KIRISHIMA, and M. MINAMI |
|
|
38 | (9) |
|
|
|
|
3.1 New Antiviral Treatment for Chronic Hepatitis B |
|
|
|
|
|
47 | (10) |
|
3.2 New Antiviral Therapy: Adefovir Dipivoxil for HBV |
|
|
|
|
|
57 | (6) |
|
3.3 Development of Entecavir: Superior Therapy for the Management of Chronic Hepatitis B Viral Infection |
|
|
|
D. DEHERTOGH, R. COLONNO, W. FISKE, and A. CROSS |
|
|
63 | (14) |
|
4 Therapy for Hepatitis B and Prevention of HCC |
|
|
|
4.1 Therapy of Hepatitis B and Prevention of Hepatocellular Carcinoma |
|
|
|
|
|
77 | (7) |
|
4.2 Differences of Clinical Characteristics Among Japanese Patients with Hepatitis B Virus Genotypes B and C |
|
|
|
|
|
84 | (13) |
|
|
|
|
5.1 Establishment of a New Hepatitis C Virus-lb Replicon |
|
|
|
N. ENOMOTO, N. SAKAMOTO, M. KUROSAKI, S. MAEKAWA, Y. TANABE, T. YAMASHIRO, C.-H. CHEN, M. NAKAGAWA, N. KANAZAWA, H. WATANABE, C. SATO, and M. WATANABE |
|
|
97 | (11) |
|
5.2 Hepatitis C Virus Replication in Cell Culture |
|
|
|
M. FRESE, V. LOHMANN, T. PIETSCHMANN, A. KAUL, N. KRIEGER, J. BUKH, and R. BARTENSCHLAGER |
|
|
108 | (15) |
|
5.3 Characterization of the Interferon Alpha Response Against HCV in Hepatoma Cells |
|
|
|
C. SEEGER, Q. ZHU, and J.-T. Guo |
|
|
123 | (10) |
|
|
|
|
6.1 Hepatitis C: Development of a Ribavirin Liver-Targeting Prodrug |
|
|
|
|
|
133 | (7) |
|
6.2 HCV Replicon Inhibitors: Mode of Action and Resistance Mapping |
|
|
|
|
|
140 | (17) |
|
7 Interferon Therapy for Hepatitis C |
|
|
|
7.1 Interferon Treatment Not Only Reduces the Risk of Hepatocellular Carcinoma But Also Improves Mortality in Patients with Chronic Hepatitis C Showing Biochemical Response, Especially in Patients with Advanced Liver Fibrosis |
|
|
|
A. KASAHARA and N. HAYASHI |
|
|
157 | (10) |
|
7.2 Favorable Outcome of Patients with C-Viral Liver Disease Treated with Interferon |
|
|
|
O. YOKOSUKA, F. IMAZEKI, S. KAWAI, and K. FUKAI |
|
|
167 | (9) |
|
7.3 IFN Receptor and IFN Signals |
|
|
|
|
|
176 | (13) |
|
8 Therapy for Hepatitis C and Prevention of HCC |
|
|
|
8.1 Management and Treatment of Hepatitis C |
|
|
|
|
|
189 | (10) |
|
8.2 Hepatitis C Virus and Hepatocellular Carcinoma |
|
|
|
|
|
199 | (10) |
|
8.3 Randomized Trial of Post-Operative Interferon Therapy After Resection of Hepatitis C Virus-Related Hepatocellular Carcinoma and Long-Term Outcome |
|
|
|
S. NISHIGUCHI and S. KUBO |
|
|
209 | (10) |
|
8.4 Roles of Antiviral Therapy in Chronic Hepatitis C Patients Should be Different According to the Stages of Liver Disease Progression |
|
|
|
|
|
219 | (10) |
|
8.5 Significance of Sustained Inflammation in the Development of HCC from HCV-Associated Cirrhotic Patients and the Prevention of HCC by Anti-Inflammatory Agents |
|
|
|
|
|
229 | (12) |
|
9 Chemoprevention and Therapy for HCC |
|
|
|
9.1 Chemoprevention of Hepatocellular Carcinoma with Retinoid |
|
|
|
|
|
241 | (8) |
|
9.2 Vitamin K2 Administration Improves the Prognoses of Patients with Hepatocellular Carcinoma Presenting High Levels of Serum Des-γ-Carboxy Prothrombin |
|
|
|
Y. KOIKE, Y. SHIRATORI, H. YOSHIDA, and M. OMATA |
|
|
249 | (2) |
|
9.3 Combination Chemotherapy for Advanced Hepatocellular Carcinoma |
|
|
|
|
|
251 | (7) |
|
9.4 Combined Intra-Arterial 5-Fluorouracil and Subcutaneous Interferon-Alpha Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombi in the Major Portal Branches |
|
|
|
M. MONDEN, M. SAKON, and H. NAGANO |
|
|
258 | (15) |
| 10 Transplantation for HBV and HCV |
|
|
10.1 Liver Transplantation for Hepatitis B Virus-Related Liver Disease |
|
|
|
S.B. PORTER and K.R. REDDY |
|
|
273 | (10) |
|
10.2 Living Donor Liver Transplantation for Hepatitis B and C Cirrhosis |
|
|
|
Y. SUGAWARA and M. MAKUUCHI |
|
|
283 | (10) |
|
10.3 Living Donor Liver Transplantation for HBV-/HCV-Related Diseases |
|
|
|
|
|
293 | |
